RPE65 and Leber congenital amaurosis: In December 2017, the FDA approved voretigene neparvovec‐rzyl (Luxturna), a gene therapy‐based drug, for the treatment of Leber congenital amaurosis (LCA) caused by biallelic retinal pigment epithelium‐specific 65‐kDa protein gene (RPE65).